Australia's most trusted
source of pharma news
Tuesday, 21 July 2026
Posted 21 July 2026 PM
Telix is predicting revenues of more than a billion US dollars for the calendar year 2026, which would be a 25 per cent increase on 2025.
After releasing its second quarter results Telix said it expects revenue for the year to be at the upper end of the guidance of $1.355-1.384 billion (US$950-970 million), with the addition of $57 million (US$40 million) from a deal with Regeneron.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.